RxDoctor Payments Data

Anuj Gupta, MD

Interventional Cardiology · Baltimore, MDNPI 1033323399

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,125 of the $13,554 with a category attached, or 96.8%. Siemens Medical Solutions USA, Inc. accounts for 96.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $7,020 and has fallen 99.3% since, to $51 in 2025.

$13,554in general payments, 2019–2025

Across 11 payments — averaging $1232.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$13K
  • Abbott$181
  • Argon Medical Devices, Inc.$90
  • Johnson & Johnson$38
  • Si-bone, Inc.$30
  • Merck$27
  • plus $62 from 3 others
$317,732in research payments, 2019–2025

Across 54 payments — averaging $5883.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$149K
  • Amgen$58K
  • Ortho-clinical Diagnostics, Inc.$46K
  • Ionis Pharmaceuticals, Inc.$35K
  • Edwards Lifesciences$25K
  • Bayer$4K

What the payments were for

  • Consulting fees$13,12597%
  • Food & beverage$3913%
  • Education$380%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,554 in reported general payments places this provider in the 60th percentile of 71 interventional cardiology providers in Maryland.

See all interventional cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$127,403
Medicare patients
1,336
Services billed
3,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$51,483
EntrestoSacubitril/Valsartan19$31,881
MounjaroTirzepatide15$25,630
XareltoRivaroxaban13$7,716
Rosuvastatin Calcium88$3,314
Ezetimibe24$2,680
VascepaIcosapent Ethyl11$2,033
Metoprolol Succinate50$1,074
Valsartan13$506
Amlodipine Besylate44$383
Furosemide33$206
Spironolactone27$192
Atorvastatin Calcium16$174
Lisinopril13$147
Carvedilol16$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$38$7,71613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 71 interventional cardiology providers in Maryland.

Other interventional cardiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →